Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 25;384(12):1168-1170.
doi: 10.1056/NEJMc2031965.

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors

Benoit Rousseau  1 , Michael B Foote  1 , Steven B Maron  1 , Bill H Diplas  1 , Steve Lu  2 , Guillem Argilés  3 , Andrea Cercek  3 , Luis A Diaz Jr  3
Affiliations

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors

Benoit Rousseau et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Effect of Immune Checkpoint Inhibitors on Survival in Patients with Tumors with High Tumor Mutational Burden.
Shown are Kaplan–Meier plots of overall survival in 137 patients with advanced colorectal cancer according to tumor mutational burden (TMB; Panel A) and the same cohort of patients with advanced colorectal cancer stratified according to tumor mutational burden, mismatch-repair–deficient (MMRd) and mismatch-repair–proficient (MMRp) status, and pol-deficient (pol-d) status (Panel B). A subgroup analysis (Panel C) shows hazard ratios for death according to tumor type in a separate cohort of 1661 patients with MMRp tumors treated with immune checkpoint inhibitors. Patients with various tumor types were combined into two separate models according to whether tumor mutational burden of 10 or more mutations per megabase significantly predicted benefit from immune checkpoint inhibitors when accounting for mismatch-repair–deficient and pol-d status. Other tumors include kidney, breast, and neuroendocrine tumors, uveal melanoma, and mucosal melanoma (see the Methods Section, Table S4 in Supplementary Appendix 2 [legend in Supplementary Appendix 1]). All hazard ratios were calculated with the use of Cox proportional-hazards univariate regression. CI denotes confidence interval, Mb megabase, NE could not be estimated, NR not reached, and NSCLC non–small-cell lung cancer.
See this image and copyright information in PMC

Comment in

References

    1. Food and Drug Administration. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. June 17, 2020. (https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pemb...).
    1. Marabelle A, Fakih M, Lopez J, et al.Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21: 1353–65. - PubMed
    1. Samstein RM, Lee C-H, Shoushtari AN, et al.Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019; 51: 202–6. - PMC - PubMed
    1. Le DT, Durham JN, Smith KN, et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357: 409–13. - PMC - PubMed
    1. Rousseau B, Bieche I, Pasmant T, et al.High activity of Nivolumab in patients with pathogenic exonucleasic domain POLE mutated mismatch repair proficient advanced tumors. Ann Oncol 2020;31: Suppl 4: 5260. abstract.

Publication types

Substances